Rani Therapeutics Holdings Inc Cl A (RANI)

$1.31 -0.01 (-0.76%)
Market Cap 75.05M
Revenue (ttm) 0.00
Net Income (ttm) -33.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 4.90
Volume 121,200
Avg Vol 493,716
Day's Range N/A - N/A
Shares Out 57.29M
Stochastic %K 19%
Beta 0.16
Analysts Strong Sell
Price Target $11.33

Latest News on RANI

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 15, 2024, 8:30 AM EDT - 3 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 4:05 PM EDT - 3 months ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Rani Therapeutics to Participate in September Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 4 months ago

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Aug 6, 2024, 4:05 PM EDT - 5 months ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics to Participate in August Investor Conferences

Jul 29, 2024, 4:05 PM EDT - 6 months ago

Rani Therapeutics to Participate in August Investor Conferences

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jul 22, 2024, 8:30 AM EDT - 6 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Jun 24, 2024, 7:00 AM EDT - 7 months ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Rani Therapeutics to Participate in May Investor Conferences

May 14, 2024, 8:00 AM EDT - 8 months ago

Rani Therapeutics to Participate in May Investor Conferences

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 9, 2024, 8:00 AM EDT - 9 months ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

May 6, 2024, 4:05 PM EDT - 9 months ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 7:05 PM EDT - 10 months ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 20, 2024, 4:05 PM EDT - 10 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 15, 2024, 4:05 PM EDT - 11 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Dec 14, 2023, 8:00 AM EST - 1 year ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Nov 8, 2023, 4:05 PM EST - 1 year ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 19, 2023, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Oct 12, 2023, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 19, 2023, 6:36 AM EDT - 1 year ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 18, 2023, 8:00 AM EDT - 1 year ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Sep 7, 2023, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Aug 11, 2023, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 21, 2023, 8:00 AM EDT - 1 year ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 8, 2023, 8:00 AM EDT - 1 year ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 31, 2023, 8:00 AM EDT - 1 year ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 24, 2023, 8:00 AM EDT - 1 year ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

May 10, 2023, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

May 5, 2023, 5:33 PM EDT - 1 year ago

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Apr 11, 2023, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rani Therapeutics Holdings, Inc. (RANI) Q4 2022 Earnings Call Transcript

Mar 22, 2023, 6:43 PM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2022 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

Mar 22, 2023, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Mar 16, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

Jan 9, 2023, 8:30 AM EST - 2 years ago

Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

Jan 5, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

Dec 6, 2022, 4:05 PM EST - 2 years ago

Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

Rani Therapeutics to Present at the Stifel Healthcare Conference

Nov 9, 2022, 4:05 PM EST - 2 years ago

Rani Therapeutics to Present at the Stifel Healthcare Conference

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

Oct 24, 2022, 8:30 AM EDT - 2 years ago

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock

Aug 11, 2022, 11:47 PM EDT - 2 years ago

Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock

Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock

Aug 10, 2022, 5:28 PM EDT - 2 years ago

Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock

Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update

Aug 10, 2022, 4:28 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

Aug 10, 2022, 4:23 PM EDT - 2 years ago

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development

Aug 8, 2022, 8:30 AM EDT - 2 years ago

Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development

Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update

May 11, 2022, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update

Rani Therapeutics to Present at Upcoming Investor Conferences

May 3, 2022, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present at Upcoming Investor Conferences

Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Apr 7, 2022, 4:05 PM EDT - 3 years ago

Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Rani Therapeutics Holdings, Inc. (RANI) Talat Imran on Q4 2021 Results - Earnings Call Transcript

Mar 29, 2022, 9:18 PM EDT - 3 years ago

Rani Therapeutics Holdings, Inc. (RANI) Talat Imran on Q4 2021 Results - Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update

Mar 29, 2022, 4:05 PM EDT - 3 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update